1Vanlet P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes:Con- sensus statements and report from a working conference[J]. Leuk Res,2007,31(6):727 - 736.
2Jabbour E,Kantarjian HM,Koller C,et al. Red blood cell transfu- sions and iron overload in the treatment of Spatients with myelo- dysplastic syndromes[J]. Cancer,2008,112(5) :1089 - 1095.
2Jabbour E, Kantarjian HM, Koller C, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodyplastie syndromes. Cancer, 2008, 112(5): 1089-1095.
3NCCN Practice Guidelines in Oncolog-v. 2. 2008. Myelodysplastic syndromes.
4Le Lan C, Loreal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood, 2005, 105(11): 4527- 4531.
5Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol, 2005,23(30) ~7594-7603.
6Takatoku TU, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol, 2007,78 (6) 487-494.
7Armand P, Kim HT, Culter CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood, 2007, 109 (10) 4586-4588.
8Allan RW. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature. Hematology, 2007, 12(6):493 496.
9Giagounidis A, Fenaux P, Mufti G J, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol, 2008, 87 (5): 345- 352.
10Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromesz a Canadian consensus guideline. Leuk Res, 2008, 32(9):1338-1353.
